Commercial GrowthNear-term commercial growth is expected based on ongoing direct-to-consumer advertising campaigns, which are targeting new prescriptions and directing efforts towards approximately 9 million Demodex blepharitis and overlapping ophthalmic disease patients.
Market PenetrationAnalyst's positive sentiment towards the ongoing XDEMVY launch has led to increased market penetration and revenue estimates due to the expansion of the prescriber base with over 20,000 eye care providers prescribing XDEMVY.
Sales PerformanceXDEMVY has achieved quarterly net product sales surpassing $100 million per quarter, reflecting its status as the first and only FDA-approved therapy to treat Demodex blepharitis.